Shield Therapeutics PLC
LSE:STX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Kanzhun Ltd
HKEX:2076
|
CN |
|
S
|
SBI Cards and Payment Services Ltd
NSE:SBICARD
|
IN |
|
Zimmer Biomet Holdings Inc
NYSE:ZBH
|
US |
Shield Therapeutics PLC
Intangible Assets
Shield Therapeutics PLC
Intangible Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Intangible Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Shield Therapeutics PLC
LSE:STX
|
Intangible Assets
£18.9m
|
CAGR 3-Years
10%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
44%
|
|
|
GlaxoSmithKline PLC
LSE:GSK
|
Intangible Assets
£16.7B
|
CAGR 3-Years
5%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
0%
|
|
|
AstraZeneca PLC
LSE:AZN
|
Intangible Assets
$37.8B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
13%
|
CAGR 10-Years
5%
|
|
|
Hikma Pharmaceuticals PLC
LSE:HIK
|
Intangible Assets
$777m
|
CAGR 3-Years
2%
|
CAGR 5-Years
6%
|
CAGR 10-Years
2%
|
|
|
Allergy Therapeutics PLC
LSE:AGY
|
Intangible Assets
£931k
|
CAGR 3-Years
-18%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-7%
|
|
|
A
|
Alliance Pharma PLC
LSE:APH
|
Intangible Assets
£240.9m
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
11%
|
|
Shield Therapeutics PLC
Glance View
Shield Therapeutics Plc is a pharmaceutical company. The company is headquartered in Gateshead, Tyne And Wear and currently employs 16 full-time employees. The company went IPO on 2016-02-26. The firm specializes in the development and commercialization of late-stage pharmaceuticals which address areas of unmet medical need. The firm's lead product, Feraccru/Accrufer (ferric maltol), is a stable, non-salt-based oral therapy for adults with iron deficiency with or without anemia. Ferric maltol is approved in the United States, European Union, United Kingdom and Switzerland for the treatment of iron deficiency with or without anemia in adults. Its pipeline product candidate, PT20, is an iron-based phosphate binder that has the potential to treat patients with hyperphosphatemia related to dialysis or non-dialysis dependent chronic kidney disease (CKD). PT20 has completed its Phase II pivotal study. Its subsidiaries include Shield Therapeutics (DE) GmbH, Shield TX (UK) Limited, Phosphate Therapeutics Limited, and others.
See Also
What is Shield Therapeutics PLC's Intangible Assets?
Intangible Assets
18.9m
GBP
Based on the financial report for Dec 31, 2025, Shield Therapeutics PLC's Intangible Assets amounts to 18.9m GBP.
What is Shield Therapeutics PLC's Intangible Assets growth rate?
Intangible Assets CAGR 10Y
44%
Over the last year, the Intangible Assets growth was 4%. The average annual Intangible Assets growth rates for Shield Therapeutics PLC have been 10% over the past three years , -7% over the past five years , and 44% over the past ten years .
